Expression of Growth Factor Receptors, the Focal Adhesion Kinase, and Other Tyrosine Kinases in Human Soft Tissue Tumors
Overview
Authors
Affiliations
Background: The tyrosine kinases are a family of genes that includes many growth factor receptors and protooncogenes. They appear to have a role in many cancers, but have not been systematically studied in the pathogenesis and progression of human sarcomas.
Methods: To characterize the protein tyrosine kinases that are expressed in human sarcomas, we used a polymerase chain reaction (PCR)-based method to construct kinase-specific cDNA libraries from low-grade and high-grade primary tumors. Thereafter, individual tyrosine kinase gene expression was assessed in a panel of sarcoma cell lines and primary tumors using Northern blotting and PCR.
Results: We identified 19 species of tyrosine kinase genes, including many growth factor receptors, the human homolog of the focal adhesion kinase (FAK) gene, and a novel trk-related kinase designated HGK2. Messenger RNA expression analyses showed relative overexpression of the two forms of the platelet-derived growth factor receptors (PDGFRs) with expression of the alpha form restricted to a subgroup of high-grad and metastatic sarcomas. We were unable to demonstrate coexpression of the PDGF isoforms in primary tumors that overexpressed the receptors, suggesting that a PDGF/PDGFR autocrine pathway may not be a central mechanism in the malignant transformation of sarcomas in vivo. FAK expression was observed in a variety of sarcomas, with increased levels in several high-grade and metastatic leiomyosarcomas.
Conclusions: When grouped together by histologic cell type and grade, the expression data of the 19 kinases in primary tumors described a greater degree of heterogeneity than is generally appreciated by clinicopathologic classification schemes. This diversity suggests that sarcomas, even those that appear to be clinically similar, arise through a variety of molecular pathways involving tyrosine kinases.
Kokkali S, Moreno J, Klijanienko J, Theocharis S Int J Mol Sci. 2022; 23(8).
PMID: 35456944 PMC: 9029574. DOI: 10.3390/ijms23084125.
Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit.
Dall G, Hamilton A, Ratnayake G, Scott C, Barker H Cancers (Basel). 2022; 14(6).
PMID: 35326717 PMC: 8946513. DOI: 10.3390/cancers14061561.
Lopez-Acevedo M, Grace L, Teoh D, Whitaker R, Adams D, Jia J Gynecol Oncol Res Pract. 2016; 1:2.
PMID: 27231555 PMC: 4877815. DOI: 10.1186/2053-6844-1-2.
Soluble AXL: a possible circulating biomarker for neurofibromatosis type 1 related tumor burden.
Johansson G, Peng P, Huang P, Chien H, Hua K, Kuo M PLoS One. 2015; 9(12):e115916.
PMID: 25551830 PMC: 4281253. DOI: 10.1371/journal.pone.0115916.
Meyer J, Perlewitz K, Hayden J, Doung Y, Hung A, Vetto J Clin Cancer Res. 2013; 19(24):6902-11.
PMID: 24132922 PMC: 3869565. DOI: 10.1158/1078-0432.CCR-13-1594.